Sunesis Pharmaceuticals, Inc. (NASDAQ:SNSS)‘s stock had its “hold” rating reaffirmed by equities research analysts at Cowen and Company in a research report issued to clients and investors on Thursday, November 2nd.
The analysts wrote, “Sunesis reported Q3 Net loss of $9.9MM and pro forma September 30 cash of.””
Other equities research analysts have also issued reports about the stock. Zacks Investment Research lowered shares of Sunesis Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Tuesday, July 11th. Cantor Fitzgerald reissued a “hold” rating and issued a $3.00 price target on shares of Sunesis Pharmaceuticals in a report on Thursday, July 27th. Finally, ValuEngine cut shares of Sunesis Pharmaceuticals from a “sell” rating to a “strong sell” rating in a research report on Friday, September 1st.
Shares of Sunesis Pharmaceuticals (NASDAQ SNSS) traded down $0.07 during mid-day trading on Thursday, reaching $2.66. The company’s stock had a trading volume of 71,600 shares, compared to its average volume of 121,689. The company has a debt-to-equity ratio of -0.34, a current ratio of 1.84 and a quick ratio of 1.84. Sunesis Pharmaceuticals has a 12 month low of $1.82 and a 12 month high of $4.45.
Sunesis Pharmaceuticals (NASDAQ:SNSS) last released its quarterly earnings results on Thursday, November 2nd. The biopharmaceutical company reported ($0.43) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.37) by ($0.06). During the same quarter last year, the company earned ($0.62) EPS. analysts predict that Sunesis Pharmaceuticals will post -1.57 earnings per share for the current fiscal year.
TRADEMARK VIOLATION WARNING: This piece of content was reported by Week Herald and is the property of of Week Herald. If you are reading this piece of content on another publication, it was stolen and republished in violation of U.S. and international trademark and copyright laws. The correct version of this piece of content can be viewed at https://weekherald.com/2017/11/14/sunesis-pharmaceuticals-inc-snss-receives-hold-rating-from-cowen-and-company.html.
In related news, Director Dayton Misfeldt bought 400,000 shares of the stock in a transaction on Friday, October 27th. The shares were purchased at an average price of $2.00 per share, for a total transaction of $800,000.00. The purchase was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, major shareholder Mpm Oncology Impact Management bought 25,300 shares of the business’s stock in a transaction that occurred on Thursday, November 2nd. The stock was purchased at an average cost of $2.59 per share, for a total transaction of $65,527.00. The disclosure for this purchase can be found here. Insiders bought 506,800 shares of company stock worth $1,091,282 over the last ninety days. Corporate insiders own 10.21% of the company’s stock.
Institutional investors and hedge funds have recently made changes to their positions in the company. Renaissance Technologies LLC grew its stake in Sunesis Pharmaceuticals by 1.1% during the first quarter. Renaissance Technologies LLC now owns 111,811 shares of the biopharmaceutical company’s stock worth $458,000 after buying an additional 1,230 shares during the last quarter. Sphera Funds Management LTD. raised its stake in Sunesis Pharmaceuticals by 54.6% in the 2nd quarter. Sphera Funds Management LTD. now owns 193,212 shares of the biopharmaceutical company’s stock worth $522,000 after purchasing an additional 68,212 shares in the last quarter. Wells Fargo & Company MN raised its position in shares of Sunesis Pharmaceuticals by 77.4% in the 2nd quarter. Wells Fargo & Company MN now owns 41,851 shares of the biopharmaceutical company’s stock valued at $113,000 after buying an additional 18,254 shares in the last quarter. Vanguard Group Inc. raised its position in shares of Sunesis Pharmaceuticals by 4.1% in the 2nd quarter. Vanguard Group Inc. now owns 605,759 shares of the biopharmaceutical company’s stock valued at $1,635,000 after buying an additional 23,819 shares in the last quarter. Finally, Virtu KCG Holdings LLC bought a new stake in shares of Sunesis Pharmaceuticals during the 2nd quarter valued at approximately $208,000. 56.43% of the stock is owned by institutional investors and hedge funds.
Sunesis Pharmaceuticals Company Profile
Sunesis Pharmaceuticals, Inc is a biopharmaceutical company. The Company focuses on the development and commercialization of its pipeline of oncology therapeutics for the treatment of solid and hematologic cancers. The Company offers QINPREZO (vosaroxin), which is a product candidate for the treatment of acute myeloid leukemia (AML).
Receive News & Ratings for Sunesis Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sunesis Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.